Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2022-09-15 5:00 pm Sale | 13D | Akero Therapeutics, Inc. AKRO | venBio Global Strategic Fund II L.P. | 714,000 1.9% | -1,601,893 (-69.17%) | View |
| 2022-06-07 4:15 pm Sale | 13G | Checkmate Pharmaceuticals Inc. CMPI | venBio Global Strategic Fund II L.P. | 0 0% | -2,535,158 (Position Closed) | View |
| 2022-05-05 4:15 pm Sale | 13G | Checkmate Pharmaceuticals Inc. CMPI | venBio Global Strategic Fund II L.P. | 2,535,158 11.5% | -1,138,216 (-30.99%) | View |
| 2022-02-14 2:30 pm Sale | 13G | Harmony Biosciences Holdings, Inc. HRMY | venBio Global Strategic Fund II L.P. | 2,740,411 4.7% | -764,213 (-21.81%) | View |
| 2021-05-07 4:13 pm Sale | 13D | Akero Therapeutics, Inc. AKRO | venBio Global Strategic Fund II L.P. | 2,315,893 6.65% | -352,824 (-13.22%) | View |
| 2021-05-07 1:01 pm Purchase | 13G | Impel Pharmaceuticals Inc. IMPL | venBio Global Strategic Fund II L.P. | 2,759,791 14.2% | 2,759,791 (New Position) | View |
| 2021-02-16 4:52 pm Purchase | 13G | Harmony Biosciences Holdings, Inc. HRMY | venBio Global Strategic Fund II L.P. | 3,504,624 6.2% | 3,504,624 (New Position) | View |
| 2020-10-06 3:19 pm Purchase | 13G | Checkmate Pharmaceuticals Inc. CMPI | venBio Global Strategic Fund II L.P. | 3,673,374 17.1% | 3,673,374 (New Position) | View |
| 2020-10-01 10:01 am Purchase | 13D | ALX Oncology Holdings Inc. ALXO | venBio Global Strategic Fund II L.P. | 9,799,331 26.9% | 9,799,331 (New Position) | View |
| 2020-09-09 5:26 pm Sale | 13D | Akero Therapeutics, Inc. AKRO | venBio Global Strategic Fund II L.P. | 2,668,717 7.7% | -653,421 (-19.67%) | View |
| 2020-04-16 12:47 pm Sale | 13D | VYNE Therapeutics Inc. MNLO | venBio Global Strategic Fund II L.P. | 0 0% | -1,461,552 (Position Closed) | View |
| 2020-01-15 4:27 pm Sale | 13D | Akero Therapeutics, Inc. AKRO | venBio Global Strategic Fund II L.P. | 3,322,138 11.6% | -632,720 (-16.00%) | View |
| 2019-06-26 4:20 pm Purchase | 13D | Akero Therapeutics, Inc. AKRO | venBio Global Strategic Fund II L.P. | 3,954,858 14.17% | 3,954,858 (New Position) | View |
| 2019-02-14 08:50 am Sale | 13G | Apellis Pharmaceuticals, Inc. APLS | venBio Global Strategic Fund II L.P. | 1,790,102 3.2% | -1,789,203 (-49.99%) | View |
| 2019-02-14 08:49 am Sale | 13G | Nabriva Therapeutics plc NBRV | venBio Global Strategic Fund II L.P. | 0 0% | -2,122,962 (Position Closed) | View |